11
Participants
Start Date
September 26, 2018
Primary Completion Date
March 31, 2021
Study Completion Date
July 31, 2021
Romidepsin
Romidepsin is a histone deacetylase (HDAC) inhibitor. HDACs catalyze the removal of acetyl groups from acetylated lysine residues in histones, resulting in the modulation of gene expression.
Ixazomib
Ixazomib is a reversible proteasome inhibitor. Ixazomib preferentially binds and inhibits the chymotrypsin-like activity of the beta 5 subunit of the 20S proteasome.
Indiana University Melvin and Bren Simon Cancer Center, Indianapolis
University of Michigan Comprehensive Cancer Center, Ann Arbor
Karmanos Cancer Center (Wayne State University), Detroit
University of Iowa Hospitals and Clinics, Iowa City
University of Minnesota, Minneapolis
University of Illinois Cancer Center, Chicago
Rutgers Cancer Institute of New Jersey, New Brunswick
Collaborators (1)
University of Michigan Rogel Cancer Center
OTHER
Takeda
INDUSTRY
Ryan Wilcox
OTHER